Tumor necrosis factor-α -308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to

Iman I El Gazzar1, Hanan M Fathy2, Tamer A Gheita3

  • 1Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.

Insights

Elevated serum tumor necrosis factor alpha (TNF-α) and its -308 A/G promoter polymorphism are linked to juvenile idiopathic arthritis (JIA) severity and functional disability. The GG genotype may influence TNF-α levels and disease activity in JIA patients.

Area of Science:

  • Immunology
  • Pediatric Rheumatology
  • Genetics

Background:

  • Juvenile idiopathic arthritis (JIA) is a complex autoimmune disease with significant clinical variability.
  • Tumor necrosis factor alpha (TNF-α) is a key pro-inflammatory cytokine implicated in JIA pathogenesis.
  • The TNF-α -308 A/G promoter polymorphism may affect gene expression and disease susceptibility/severity.

Purpose of the Study:

  • To investigate the clinical significance of serum TNF-α levels and the TNF-α -308 A/G promoter polymorphism in JIA patients.
  • To explore associations between these factors and JIA subsets, clinical/laboratory features, disease activity, damage, and functional disability.

Main Methods:

  • Serum TNF-α levels were measured using ELISA in 48 JIA patients and 30 controls.
  • The TNF-α -308 A/G promoter polymorphism was genotyped using polymerase chain reaction.
  • Disease activity (JADAS-27), damage (JADI), and functional status (CHAQ) were assessed.

Main Results:

  • Serum TNF-α was significantly higher in JIA patients (90.4 ng/ml) than controls (3.5 ng/ml) (p < 0.0001).
  • Elevated serum TNF-α correlated with higher JADAS-27 and CHAQ scores, and negatively with the GG genotype.
  • The GG genotype showed a negative association with C-reactive protein and tended to correlate negatively with JADAS-27, CHAQ, and JADI-extrarticular.

Conclusions:

  • Serum TNF-α levels and the -308 A/G polymorphism are clinically significant in JIA.
  • The GG genotype may be associated with lower TNF-α production and potentially milder disease phenotypes or better response to treatment.
  • These findings suggest a role for TNF-α genetic variations in modulating JIA severity and influencing anti-TNF-α therapy outcomes.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
TGF - &#946; Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660